Well Researched

Efpeglenatide

GLP & Metabolic · LAPSExendin4, HM11260C

A long-acting GLP-1 receptor agonist built from an exendin-4 analog conjugated to an immunoglobulin Fc fragment, studied in glucose regulation and cardiorenal outcome research.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Research Level

Well Researched

Browse the store →

🧬

Efpeglenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist composed of a single-amino-acid-modified exendin-4 analog (CA-exendin-4) conjugated to a human immunoglobulin Fc fragment through a short polyethylene-glycol linker. The Fc conjugation is described in the literature as extending its circulating half-life to support infrequent dosing schedules in trials.

It has been evaluated across the AMPLITUDE clinical program in type 2 diabetes, including a large cardiovascular and renal outcomes trial, making it a well-characterized member of the GLP-1 receptor agonist class in outcome research.

Like other GLP-1 receptor agonists, efpeglenatide engages the GLP-1 receptor, a class B GPCR, driving Gas/cAMP signaling associated in study models with glucose-dependent insulin secretion, slowed gastric emptying, and central appetite pathways [1].

The exendin-4-derived backbone confers resistance to dipeptidyl peptidase-4 degradation, and the Fc/PEG conjugation is reported to prolong exposure relative to native GLP-1.

Glycemic regulation - studied for HbA1c and glucose-dependent insulin secretion in type 2 diabetes cohorts [2].
Cardiovascular outcomes - investigated in a dedicated CV/renal outcomes trial [1].
Renal endpoints - examined for composite kidney outcomes in the same program [1].
Body-weight and lipid measures - reported as secondary study endpoints [2].

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

In the AMPLITUDE-O trial, investigators randomized participants with type 2 diabetes and cardiovascular or renal risk to weekly subcutaneous efpeglenatide (4 mg or 6 mg) or placebo and reported a lower incidence of major adverse cardiovascular events in the efpeglenatide groups [1].

In the AMPLITUDE-M randomized controlled trial, researchers studied once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes and reported changes in HbA1c and body weight [2].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

SemaglutideNeutral

Both are GLP-1 receptor agonists; compared within the drug class rather than combined.

TirzepatideNeutral

Related incretin-based research pipeline; studied comparatively, not together.

InsulinCaution

Combined glucose-lowering agents are studied for additive effects on blood glucose in clinical literature.

What makes efpeglenatide long-acting?

Published descriptions attribute its extended half-life to an exendin-4 analog conjugated to an immunoglobulin Fc fragment via a PEG linker [1].

What has it been studied for?

Primarily glycemic control in type 2 diabetes and cardiovascular/renal outcomes in the AMPLITUDE program [1][2].

Is this product intended for human use?

No. This entry is for research and informational purposes only and is not dosing guidance or a therapeutic recommendation.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.